Search alternatives:
system decrease » step decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
ai large » a large (Expand Search), via large (Expand Search), _ large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
system decrease » step decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
ai large » a large (Expand Search), via large (Expand Search), _ large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
-
1
-
2
-
3
Feasibility of AI-powered assessment scoring: Can large language models replace human raters?
Published 2025“…<p><b>Objective:</b> To assess the feasibility, accuracy, and reliability of using ChatGPT-4.5 (early-access), a large language model (LLM), for automated scoring of Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) protocols. …”
-
4
-
5
-
6
-
7
-
8
-
9
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
Published 2025“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. (B) Even though higher proportions of mutualism promote higher richness, introducing this type of interaction into already assembled large communities promotes a sudden drop in richness, while stopping mutualism promotes a slight boost in richness increase. …”
-
10
-
11
-
12
-
13
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
14
-
15
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
17
-
18
-
19
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
20